5,157 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Bought by Northern Trust Corp

Northern Trust Corp acquired a new stake in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,157 shares of the company’s stock, valued at approximately $205,000. Northern Trust Corp owned approximately 0.14% of Aligos Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its position in shares of Aligos Therapeutics by 2,073.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock valued at $26,000 after buying an additional 622 shares during the last quarter. Golden State Wealth Management LLC bought a new position in shares of Aligos Therapeutics during the 4th quarter worth approximately $107,000. Charles Schwab Investment Management Inc. lifted its position in Aligos Therapeutics by 19.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock valued at $569,000 after acquiring an additional 2,306 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in Aligos Therapeutics during the fourth quarter valued at approximately $739,000. Finally, Wells Fargo & Company MN acquired a new stake in Aligos Therapeutics in the fourth quarter valued at approximately $869,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Aligos Therapeutics in a report on Monday, March 31st.

Aligos Therapeutics Price Performance

Shares of ALGS stock opened at $5.25 on Tuesday. Aligos Therapeutics, Inc. has a 1-year low of $3.76 and a 1-year high of $46.80. The stock’s fifty day moving average price is $5.57 and its 200 day moving average price is $18.66. The company has a market cap of $32.10 million, a price-to-earnings ratio of -0.39 and a beta of 2.76.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($2.11) EPS for the quarter, beating analysts’ consensus estimates of ($2.80) by $0.69. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.33 million. As a group, equities research analysts anticipate that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).